{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T21:12:35Z","timestamp":1767906755684,"version":"3.49.0"},"reference-count":21,"publisher":"Georg Thieme Verlag KG","issue":"22","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dtsch Med Wochenschr"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:title>\u201eWas ist neu?\u201c<\/jats:title><jats:p>\n          Behandlungsziele bei diabetischer Nephropathie:\u2002Eine neue Einteilung von Patienten mit Diabetes mellitus in sog. Cluster kann zur Risikoeinsch\u00e4tzung der Entwicklung einer diabetischen Nephropathie herangezogen werden. Die Behandlung von Patienten mit diabetischer Nephropathie umfasst l\u00e4ngst nicht mehr die reine Blutzuckerkontrolle, sondern stellt einen gesamtheitlichen Ansatz der (Progressions-) Vermeidung diabetischer Folgekomplikationen und Senkung der kardiovaskul\u00e4ren Mortalit\u00e4t des Patienten in den Mittelpunkt.<\/jats:p><jats:p>\n          S\u00e4ulen der Behandlung bei diabetischer Nephropathie:\u2002Um diese Behandlungsziele zu erreichen, ben\u00f6tigt es eine umfassende Betreuung des Patienten zur Umsetzung von Lebensstil-Interventionen (hinsichtlich Ern\u00e4hrung, k\u00f6rperlicher Aktivit\u00e4t, Gewichtsabnahme, Raucherentw\u00f6hnung) und Auswahl der medikament\u00f6sen Therapie mit dem gr\u00f6\u00dftm\u00f6glichen individuellen Nutzen.<\/jats:p><jats:p>\n          Ern\u00e4hrungsempfehlungen bei diabetischer Nephropathie:\u2002Teil der Lebensstil-Intervention ist die Einhaltung einer Ern\u00e4hrungsform, die sich in aktuellen Studien erneut als relevanter Bestandteil der Progressionshemmung der chronischen Nierenerkrankung und der Senkung des kardiovaskul\u00e4ren Risikos erwiesen hat. Dazu geh\u00f6ren insbesondere eine Proteinrestriktion mit Bevorzugung pflanzlicher Proteinquellen und eine Kochsalzrestriktion.<\/jats:p><jats:p>\n          Einsatz von medikament\u00f6sen Substanzen mit nachgewiesenem kardiorenalem Nutzen:\u2002Die Anpassung einer medikament\u00f6sen Therapie erfolgt nicht mehr nur anhand der antihyperglyk\u00e4mischen Effekte, sondern ber\u00fccksichtigt die Progressionshemmung der Nephropathie und das kardiale Risiko sowie die Unterst\u00fctzung einer Gewichtsreduktion. Hierzu stehen zus\u00e4tzlich zu den RAAS-Inhibitoren aus dem Bereich der Antihypertensiva nun die Antidiabetika-Klassen der SGLT2-Inhibitoren und GLP-1-Rezeptor-Agonisten sowie der nicht steroidale Aldosteron-Antagonist Finerenon zur Verf\u00fcgung.<\/jats:p>","DOI":"10.1055\/a-1911-0201","type":"journal-article","created":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T23:40:51Z","timestamp":1667346051000},"page":"1476-1481","source":"Crossref","is-referenced-by-count":3,"title":["Behandlungsstrategien bei diabetischer Nephropathie \u2013 Update 2022"],"prefix":"10.1055","volume":"147","author":[{"given":"Anja","family":"Schork","sequence":"additional","affiliation":[{"name":"Department f\u00fcr Innere Medizin, Abt. IV (Endokrinologie, Diabetologie und Nephrologie), Universit\u00e4tsklinikum T\u00fcbingen"},{"name":"Institut f\u00fcr Diabetesforschung und Metabolische Erkrankungen des Helmholtz-Zentrums M\u00fcnchen an\u00a0der\u00a0Eberhard-Karls-Universit\u00e4t T\u00fcbingen"},{"name":"Deutsches Zentrum f\u00fcr Diabetesforschung (DZD), Universit\u00e4tsklinikum T\u00fcbingen"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ferruh","family":"Artunc","sequence":"additional","affiliation":[{"name":"Department f\u00fcr Innere Medizin, Abt. IV (Endokrinologie, Diabetologie und Nephrologie), Universit\u00e4tsklinikum T\u00fcbingen"},{"name":"Institut f\u00fcr Diabetesforschung und Metabolische Erkrankungen des Helmholtz-Zentrums M\u00fcnchen an\u00a0der\u00a0Eberhard-Karls-Universit\u00e4t T\u00fcbingen"},{"name":"Deutsches Zentrum f\u00fcr Diabetesforschung (DZD), Universit\u00e4tsklinikum T\u00fcbingen"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2022,11,1]]},"reference":[{"key":"ref1","first-page":"S1","article-title":"KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group","author":"[Anonym]","year":"2020","journal-title":"Kidney International"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/s2213-8587(18)30051-2","article-title":"Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables","volume":"6","author":"E Ahlqvist","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41591-020-1116-9","article-title":"Pathophysiology-based subphenotyping of individuals at elevated risk for type 2 diabetes","volume":"27","author":"R Wagner","year":"2021","journal-title":"Nat Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"S144","DOI":"10.2337\/dc22-S010","article-title":"10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2022","volume":"45","author":"[Anonym]","year":"2022","journal-title":"Diabetes Care"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1001\/archinte.164.6.659","article-title":"Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization","volume":"164","author":"D S Keith","year":"2004","journal-title":"Arch Intern Med"},{"key":"ref6","volume-title":"Diabetische Nephropathie. In Diabetologie in Klinik und Praxis","author":"F KM Artunc","year":"2021"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1093\/ndt\/gft249","article-title":"Reduction and residual proteinuria are therapeutic targets in type 2 diabetes with overt nephropathy: a post hoc analysis (ORIENT-proteinuria)","volume":"28","author":"E Imai","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"9062","DOI":"10.1038\/s41598-022-13054-y","article-title":"Renal protection induced by physical exercise may be mediated by the irisin\/AMPK axis in diabetic nephropathy","volume":"12","author":"G P Formigari","year":"2022","journal-title":"Sci Rep"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH)","volume":"39","author":"B Williams","year":"2018","journal-title":"European Heart Journal"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1681\/asn.2016030248","article-title":"Red Meat Intake and Risk of ESRD","volume":"28","author":"Q J Lew","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1056\/nejm199403313301301","article-title":"The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group","volume":"330","author":"S Klahr","year":"1994","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1056\/NEJMc1611290","article-title":"Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes","volume":"375","author":"C Wanner","year":"2016","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/ki.1990.178","article-title":"Renal, metabolic and hormonal responses to ingestion of animal and vegetable proteins","volume":"38","author":"P Kontessis","year":"1990","journal-title":"Kidney Int"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1161\/circulationaha.120.050371","article-title":"Blood Pressure Effects of Sodium Reduction: Dose-Response Meta-Analysis of Experimental Studies","volume":"143","author":"T Filippini","year":"2021","journal-title":"Circulation"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/s0007114522002094","article-title":"Diet therapy along with Nutrition Education can Improve Renal Function in People with Stages 3-4 chronic kidney disease who do not have diabetes. (A randomized controlled trial)","author":"M Hamidianshirazi","year":"2022","journal-title":"Br J Nutr"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"S275","DOI":"10.1093\/advances\/nmy117","article-title":"Plant-Based Diets for Personal, Population, and Planetary Health","volume":"10","author":"E C Hemler","year":"2019","journal-title":"Adv Nutr"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in Patients with Chronic Kidney Disease","volume":"383","author":"H JL Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12933-019-0852-y","article-title":"Effect of SGLT2 inhibitors on body composition, fluid status and renin-angiotensin-aldosterone system in type 2 diabetes: a prospective study using bioimpedance spectroscopy","volume":"18","author":"A Schork","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/s2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"S L Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide Once Weekly for the Treatment of Obesity","volume":"387","author":"A M Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes","volume":"383","author":"G L Bakris","year":"2020","journal-title":"N Engl J Med"}],"container-title":["DMW - Deutsche Medizinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1911-0201.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T23:41:36Z","timestamp":1667346096000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1911-0201"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":21,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2022,11,1]]},"published-print":{"date-parts":[[2022,11]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1911-0201","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0012-0472","1439-4413"],"issn-type":[{"value":"0012-0472","type":"print"},{"value":"1439-4413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11]]}}}